My laboratory is focused on co-developing and translating molecularly targeted, ultrasmall particle- and cellular engineered platforms to the clinic for image-guided surgical and theranostic applications. These efforts build on long-standing diagnostic and therapeutic research programs at the nano-bio interface in a variety of tumor and other disease models. Specifically, my laboratory performs translational multi-disciplinary studies to address critical unmet needs in the fields of nanomedicine, immunotherapy, radiotherapy, and image-guided surgery. Applications are both cancer and non-cancer based. Specific efforts are directed towards co-developing nanomedicines, targeted radiotherapy, and engineered cell-based therapies for clinical care, establishing favorable pharmacokinetic, safety, and efficacy profiles, regulating the tumor microenvironment, and promoting induction of cell death programs. I have served as Principal Investigator of several Phase I/II clinical trials utilizing targeted multimodal particle-based probes for image-guided surgery in patients with prostate cancer, head and neck cancer, and malignant brain tumors, which are currently active.